$294.76
1.17% day before yesterday
NYSE, Jul 18, 10:03 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$294.76
+5.13 1.77% 1M
+22.65 8.32% 6M
+34.12 13.09% YTD
-36.21 10.94% 1Y
+50.92 20.88% 3Y
+33.81 12.96% 5Y
+130.42 79.36% 10Y
+224.26 318.10% 20Y
NYSE, Closing price Fri, Jul 18 2025
-3.49 1.17%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Basic
Market capitalization
$158.5b
Enterprise Value
$207.1b
Net debt
$48.6b
Cash
$8.8b
Shares outstanding
537.7m
Valuation (TTM | estimate)
P/E
26.9 | 13.8
P/S
4.6 | 4.4
EV/Sales
6.1 | 5.8
EV/FCF
19.0
P/B
25.5
Dividends
DPS
$9.00
Yield 1Y | 5Y
3.1% | 3.1%
Growth 1Y | 5Y
5.6% | 9.2%
Payout 1Y | 3Y
119.1% | 78.6%
Increased
14 Years
Financials (TTM | estimate)
Revenue
$34.1b | $36.0b
EBITDA
$14.2b | $20.8b
EBIT
$8.6b | $15.9b
Net Income
$5.9b | $11.5b
Free Cash Flow
$10.9b
Growth (TTM | estimate)
Revenue
15.6% | 7.7%
EBITDA
22.0% | 36.2%
EBIT
22.0% | 64.7%
Net Income
57.7% | 180.0%
Free Cash Flow
53.8%
Margin (TTM | estimate)
Gross
64.1%
EBITDA
41.6% | 57.7%
EBIT
25.2%
Net
17.4% | 31.8%
Free Cash Flow
32.0%
Financial Health
Equity Ratio
6.4%
Return on Equity
69.6%
ROCE
13.0%
ROIC
-
Debt/Equity
9.2
More
EPS
$11.0
FCF per Share
$20.3
Short interest
2.5%
Employees
28k
Rev per Employee
$1.2m
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

39 Analysts have issued a Amgen forecast:

21x Buy
54%
15x Hold
38%
3x Sell
8%

Analyst Opinions

39 Analysts have issued a Amgen forecast:

Buy
54%
Hold
38%
Sell
8%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
34,126 34,126
16% 16%
100%
- Direct Costs 12,263 12,263
23% 23%
36%
21,863 21,863
12% 12%
64%
- Selling and Administrative Expenses 6,975 6,975
4% 4%
20%
- Research and Development Expense 6,107 6,107
21% 21%
18%
14,188 14,188
22% 22%
42%
- Depreciation and Amortization 5,580 5,580
22% 22%
16%
EBIT (Operating Income) EBIT 8,608 8,608
22% 22%
25%
Net Profit 5,933 5,933
58% 58%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Neutral
Seeking Alpha
2 days ago
This week's Undercovered Dozen spotlights 12 lesser-known stocks with compelling investment theses, spanning micro-nuclear, luxury, biotech, and high-yield BDCs. Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's explosive growth in ophthalmic pharmaceuticals. Coca-Cola and Ares Capital are flagged as overvalued or increasing...
Positive
Seeking Alpha
5 days ago
Key acquisitions since 2022 increased Amgen's rare disease pipeline and footprint in the market, with the company poised to benefit from the rare disease market's 10.35% CAGR up to 2037. A growing portfolio of biosimilar products will drive double-digit sales growth in the coming decade. The immense growth potential in both its rare disease and biosimilar portfolios is essential for Amgen to of...
Positive
Seeking Alpha
5 days ago
Amgen offers an economic moat with patent protection, a robust pipeline, and strong execution, making it a defensive long-term investment. Double-digit sales growth in key drugs and a burgeoning biosimilars business support Amgen's solid revenue and earnings outlook. The pipeline, especially MariTide for obesity and biosimilars to blockbuster oncology drugs, provides meaningful future growth ca...
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 28,000
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today